title: Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells.
abstract: BACKGROUND
  The World Health Organization separates acute erythroid leukemia (erythropoiesis in ≥50% of nucleated bone marrow cells; ≥20% myeloblasts of non-erythroid cells) from other entities with increased erythropoiesis - acute myeloid leukemia with myelodysplasia-related changes (≥20% myeloblasts of all nucleated cells) or myelodysplastic syndromes - and subdivides acute erythroid leukemia into erythroleukemia and pure erythroid leukemia subtypes. We aimed to investigate the biological/genetic justification for the different categories of myeloid malignancies with increased erythropoiesis (≥50% of bone marrow cells).
  
  
  METHODS
  We investigated 212 patients (aged 18.5-88.4 years) with acute myeloid leukemia or myelodysplastic syndromes characterized by 50% or more erythropoiesis: 108 had acute myeloid leukemia (77 with acute erythroid leukemia, corresponding to erythroid/myeloid erythroleukemia, 7 with pure erythroid leukemia, 24 with acute myeloid leukemia with myelodysplasia-related changes) and 104 had myelodysplastic syndromes. Morphological and chromosome banding analyses were performed in all cases; subsets of cases were analyzed by polymerase chain reaction and immunophenotyping.
  
  
  RESULTS
  Unfavorable karyotypes were more frequent in patients with acute myeloid leukemia than in those with myelodysplastic syndromes (42.6% versus 13.5%; P<0.0001), but their frequency did not differ significantly between patients with acute erythroid leukemia (39.0%), pure erythroid leukemia (57.1%), and acute myeloid leukemia with myelodysplasia-related changes (50.0%). The incidence of molecular mutations did not differ significantly between the different categories. The 2-year overall survival rate was better for patients with myelodysplastic syndromes than for those with acute myeloid leukemia (P<0.0001), without significant differences across the different acute leukemia subtypes. The 2-year overall survival rate was worse in patients with unfavorable karyotypes than in those with intermediate risk karyotypes (P<0.0001). In multivariate analysis, only myelodysplastic syndromes versus acute myeloid leukemia (P=0.021) and cytogenetic risk category (P=0.002) had statistically significant effects on overall survival.
  
  
  CONCLUSIONS
  The separation of acute myeloid leukemia and myelodysplastic syndromes with 50% or more erythropoietic cells has clinical relevance, but it might be worth discussing whether to replace the subclassifications of different subtypes of acute erythroid leukemia and acute myeloid leukemia with myelodysplasia-related changes by the single entity, acute myeloid leukemia with increased erythropoiesis ≥50%.
authors: Department for Stem Cell Transplantation, University of Hamburg, Hamburg, Germany.
authors: Ulrike
authors: U
authors: Bacher
authors: Claudia
authors: C
authors: Haferlach
authors: Tamara
authors: T
authors: Alpermann
authors: Wolfgang
authors: W
authors: Kern
authors: Susanne
authors: S
authors: Schnittger
authors: Torsten
authors: T
authors: Haferlach
references: Blood. 2002 Nov 1;100(9):3135-40
references: 12384410
references: Leukemia. 2002 Jan;16(1):53-9
references: 11840263
references: Blood. 2005 Dec 1;106(12):3733-9
references: 16076867
references: Leukemia. 2000 May;14(5):796-804
references: 10803509
references: Haematologica. 2005 Jul;90(7):881-9
references: 15996925
references: Blood. 2004 Nov 15;104(10):3078-85
references: 15284114
references: Blood. 2006 May 15;107(10):3847-53
references: 16434492
references: Mod Pathol. 2008 Nov;21(11):1394-402
references: 18839018
references: J Clin Pathol. 2001 Aug;54(8):608-12
references: 11477115
references: Blood. 2008 Mar 1;111(5):2527-37
references: 17965322
references: Leukemia. 2009 Dec;23(12):2275-80
references: 19741728
references: Blood. 2010 Jul 22;116(3):354-65
references: 20385793
references: Blood. 2010 Mar 11;115(10):1985-92
references: 20040759
references: Leukemia. 2004 Apr;18(4):888-90
references: 14973506
references: Leukemia. 2002 Feb;16(2):196-202
references: 11840285
references: Mod Pathol. 2010 Aug;23(8):1113-26
references: 20473273
references: Blood. 2005 Dec 1;106(12):3740-6
references: 16051734
references: Blood. 2009 Sep 10;114(11):2220-31
references: 19587375
references: Leukemia. 1992 Jun;6(6):520-5
references: 1318461
references: Blood. 2006 May 15;107(10):4011-20
references: 16455956
references: Blood. 2002 Jul 1;100(1):59-66
references: 12070009
references: Blood. 2002 Jun 15;99(12):4326-35
references: 12036858
references: Haematologica. 2002 Feb;87(2):148-53
references: 11836165